Vivos Inc. has taken a significant step by filing a definitive proxy statement with the Securities and Exchange Commission (SEC) on November 9, 2026. This filing outlines key proposals that will be presented for shareholder approval, reflecting the company's commitment to transparency and corporate governance.

The importance of this filing lies in its potential impact on Vivos Inc. and the broader surgical and medical instruments industry. By engaging shareholders in the decision-making process, Vivos aims to strengthen investor confidence and align its strategies with shareholder interests. This move could set a precedent for other companies in the sector, prompting them to adopt similar practices to enhance their governance frameworks.

Background

Vivos Inc., incorporated in Delaware, operates in the surgical and medical instruments and apparatus sector, classified under SIC code 3841. The company trades on the OTC exchange under the ticker RDGL. Vivos has been active in filing various reports with the SEC, including recent submissions such as a 10-Q on November 12, 2026, and an 8-K on November 5, 2026.

What the Filing Says

The definitive proxy statement filed by Vivos Inc. includes detailed proposals that will be subject to a vote by shareholders. While specific details of the proposals were not disclosed in the filing, the document underscores the company's intention to engage its shareholders actively.

Impact

This filing may affect Vivos Inc.'s shareholders significantly, as it outlines proposals that could shape the company's future direction. Additionally, it may influence competitors within the surgical and medical instruments industry to enhance their governance practices in response to Vivos' proactive approach.

What's Next

The filing does not specify what happens next, but it indicates that shareholders will have the opportunity to vote on the proposals outlined in the proxy statement.